中华实验和临床感染病杂志（电子版）
中華實驗和臨床感染病雜誌（電子版）
중화실험화림상감염병잡지（전자판）
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Version)
2015年
5期
670-673
,共4页
肝炎,乙型,重型%拉米夫定%替比夫定%多烯磷脂酰胆碱%异甘草酸镁
肝炎,乙型,重型%拉米伕定%替比伕定%多烯燐脂酰膽堿%異甘草痠鎂
간염,을형,중형%랍미부정%체비부정%다희린지선담감%이감초산미
Severe hepatitis B%Lamivudine%Telbivudine%Polyene phosphatidylcholine%Magnesium isoglycyrrhizinate
目的 探讨替比夫定(LdT)联合异甘草酸镁(MIG)治疗重型乙型肝炎(SHB)的临床价值.方法 收集本院2010年3月至2014年8月收治67例SHB患者,随机分为对照组(31例)和观察组(36例).两组在基础治疗的基础上,对照组患者给予拉米夫定(LAM)0.1 g、1次/d口服,多烯磷脂酰胆碱0.465 g、1次/d静脉注射;治疗组患者给予LdT 0.6 g、1次/d口服,MIG 0.15 g、1次/d静脉注射.观察时间为6周,比较两组在治疗前后肝功能、生化、凝血和病毒变化情况.结果 两组患者HBV DNA低于检测下限率分别为54.8%和77.8%,差异具有统计学意义(χ2= 2.97,P< 0.05);HBV载量分别为(3.4 ± 1.3)log10拷贝/ml和(2.7 ± 0.9)log10拷贝/ml,差异具有统计学意义(t= 2.91, P< 0.01).两组患者TBil分别为(226.2 ± 147.6)μmol/L和(144.1 ± 112.3)μmol/L(t = 2.12,P< 0.05),PT分别为(27.4 ± 13.6)s和(21.6 ± 11.8)s(t = 2.03,P< 0.05),PA分别为(171.8 ± 82.1)mg/L和(223.1 ± 92.7)mg/L(t = 3.28,P< 0.01).两组患者K+(t = 0.082,P> 0.05)、Na+(t = 0.284,P> 0.05)和Cl-(t = 0.891,P> 0.05)差异均无统计学意义.结论 LdT联合MIG是治疗SHB有效而安全的配伍用药.
目的 探討替比伕定(LdT)聯閤異甘草痠鎂(MIG)治療重型乙型肝炎(SHB)的臨床價值.方法 收集本院2010年3月至2014年8月收治67例SHB患者,隨機分為對照組(31例)和觀察組(36例).兩組在基礎治療的基礎上,對照組患者給予拉米伕定(LAM)0.1 g、1次/d口服,多烯燐脂酰膽堿0.465 g、1次/d靜脈註射;治療組患者給予LdT 0.6 g、1次/d口服,MIG 0.15 g、1次/d靜脈註射.觀察時間為6週,比較兩組在治療前後肝功能、生化、凝血和病毒變化情況.結果 兩組患者HBV DNA低于檢測下限率分彆為54.8%和77.8%,差異具有統計學意義(χ2= 2.97,P< 0.05);HBV載量分彆為(3.4 ± 1.3)log10拷貝/ml和(2.7 ± 0.9)log10拷貝/ml,差異具有統計學意義(t= 2.91, P< 0.01).兩組患者TBil分彆為(226.2 ± 147.6)μmol/L和(144.1 ± 112.3)μmol/L(t = 2.12,P< 0.05),PT分彆為(27.4 ± 13.6)s和(21.6 ± 11.8)s(t = 2.03,P< 0.05),PA分彆為(171.8 ± 82.1)mg/L和(223.1 ± 92.7)mg/L(t = 3.28,P< 0.01).兩組患者K+(t = 0.082,P> 0.05)、Na+(t = 0.284,P> 0.05)和Cl-(t = 0.891,P> 0.05)差異均無統計學意義.結論 LdT聯閤MIG是治療SHB有效而安全的配伍用藥.
목적 탐토체비부정(LdT)연합이감초산미(MIG)치료중형을형간염(SHB)적림상개치.방법 수집본원2010년3월지2014년8월수치67례SHB환자,수궤분위대조조(31례)화관찰조(36례).량조재기출치료적기출상,대조조환자급여랍미부정(LAM)0.1 g、1차/d구복,다희린지선담감0.465 g、1차/d정맥주사;치료조환자급여LdT 0.6 g、1차/d구복,MIG 0.15 g、1차/d정맥주사.관찰시간위6주,비교량조재치료전후간공능、생화、응혈화병독변화정황.결과 량조환자HBV DNA저우검측하한솔분별위54.8%화77.8%,차이구유통계학의의(χ2= 2.97,P< 0.05);HBV재량분별위(3.4 ± 1.3)log10고패/ml화(2.7 ± 0.9)log10고패/ml,차이구유통계학의의(t= 2.91, P< 0.01).량조환자TBil분별위(226.2 ± 147.6)μmol/L화(144.1 ± 112.3)μmol/L(t = 2.12,P< 0.05),PT분별위(27.4 ± 13.6)s화(21.6 ± 11.8)s(t = 2.03,P< 0.05),PA분별위(171.8 ± 82.1)mg/L화(223.1 ± 92.7)mg/L(t = 3.28,P< 0.01).량조환자K+(t = 0.082,P> 0.05)、Na+(t = 0.284,P> 0.05)화Cl-(t = 0.891,P> 0.05)차이균무통계학의의.결론 LdT연합MIG시치료SHB유효이안전적배오용약.
Objective To investigate the effect of telbivudine and magnesium isoglycyrrhizinate in treatment of severe hepatitis B (SHB).Methods Total of 67 cases in March 2010 to August 2014 were randomly divided into control group (31 cases) and observation group (36 cases). Patients in the both groups all received basic treatment, the control group was added with lamivudine 0.1 g/d and polyene phosphatidylcholine 465 mg. Treatment group was added with telbivudine 0.6 g/d and magnesium isoglycyrrhizinate 0.15 g/d. The observation time was 6 weeks. The liver function and biochemical changes, blood clotting and virus in the treatment before and after were compared, respectively. Results The indexes of patients in the two groups were observed at the end of the objective efifciency, lower than the detection limit of HBV DNA were 54.8% and 77.8% (χ2= 2.97,P < 0.05). HBV loads were (3.4 ± 1.3) log10copies/ml and (2.7 ± 0.9) log10copies/ml (t = 2.91,P < 0.01). The levels of TBil were (226.2 ± 226.2) μmol/L and (144.1 ± 112.3) μmol/L (t = 2.12,P < 0.05); PT were (27.4 ± 13.6) s and (21.6 ± 11.8) s (t = 2.03,P < 0.05); PA was (171.8 ± 82.1) mg/L and (223.1 ± 92.7) mg/L (t = 3.28,P < 0.01), all with signiifcant differences. But the levels of K+(t = 0.082,P > 0.05), Na+(t = 0.284,P > 0.05) and Cl-(t = 0.891,P > 0.05) of the two groups were with no signiifcant differences.Conclusion LdT and MIG were effective and safe treatment for SHB compatibility of medicines.
